Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Plus EP/EC in First-line Genitourinary Small Cell Carcinoma
NCT05760053Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in genitourinary small cell carcinoma, sponsored by Sun Yat-sen University. Started Feb 2023; status: recruiting.
02
Drugs
toripalimab
03
Conditions
genitourinary small cell carcinoma
Beyond the preview
Go deeper on NCT05760053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05760053.